

IN THE MATTER OF

SAGENT PHARMACEUTICALS

PERMIT NO. D07324

*

*

*

*

*

BEFORE THE

MARYLAND STATE

BOARD OF PHARMACY

Case No. 25-030

* * * * *

PRE-CHARGE CONSENT ORDER

Background

The Maryland Board of Pharmacy (the "Board") received two (2) self-reports from Sagent Pharmaceuticals ("Sagent") disclosing that it had been issued non-disciplinary civil assessments by the Arkansas and Arizona Boards of Pharmacy for failing to provide timely notification of its change of ownership. The Board subsequently received information from Sagent evidencing that it had distributed prescription drug products into Maryland under its new and current ownership prior to obtaining a Maryland wholesale distributor's permit.

In lieu of instituting formal proceedings against Sagent Pharmaceuticals, in accordance with the Maryland Pharmacy Act, Md. Code Ann., Health Occ. § 12-101 *et seq.*, the Board and Sagent have agreed to resolve this matter as set forth in this Pre-Charge Consent Order.

FINDINGS OF FACT

1. At all times relevant, Sagent Pharmaceuticals was a wholesale distributor located in Schaumburg, Illinois.
2. On February 27, 2023, Sagent Pharmaceuticals was acquired by Que Pharma,

1. The first part of the document is a letter from the President of the United States to the Vice President, dated May 12, 2025. The letter is addressed to the Vice President and is signed by the President. The letter discusses the current state of the country and the challenges it faces. It also mentions the President's plans for the future and the role of the Vice President in the administration.

2. The second part of the document is a letter from the Vice President to the President, dated May 12, 2025. The letter is addressed to the President and is signed by the Vice President. The letter discusses the Vice President's views on the current state of the country and the challenges it faces. It also mentions the Vice President's plans for the future and the role of the President in the administration.

3. The third part of the document is a letter from the President to the Vice President, dated May 12, 2025. The letter is addressed to the Vice President and is signed by the President. The letter discusses the President's views on the current state of the country and the challenges it faces. It also mentions the President's plans for the future and the role of the Vice President in the administration.

Inc.; however, Sagent did not submit an application to the Board for a change in ownership until May 5, 2023.

3. Wholesale distributor permits are not transferrable.
4. On or about June 5, 2023, the Board issued a wholesale distributor's permit to Sagent Pharmaceuticals. The distributor's permit is active and expires on May 31, 2025.
5. On or about July 21, 2023, Sagent submitted a self-report to the Board disclosing that it had been assessed non-disciplinary administrative costs of \$2,500 by the Arkansas Board of Pharmacy for failing to submit timely notification of its change of ownership.
6. On or about August 29, 2023, Sagent submitted to the Board a self-report disclosing that it had been assessed a non-disciplinary civil penalty by the Arizona Board of Pharmacy for failing to submit timely notification of its change of ownership.
7. On July 31, 2023, the Board subpoenaed distribution reports from Sagent for any products dispensed, distributed or sold into Maryland prior to the issuance of the distributor's permit number D07324.
8. The distribution records from Sagent revealed that it distributed approximately 136 prescription drug products into Maryland prior to obtaining a wholesale distributor's permit from the Board.

CONCLUSIONS OF LAW

Based on the foregoing Findings of Fact, the Board concludes that Sagent Pharmaceuticals is subject to the imposition of a fine in accordance with Md. Code Ann., Health Occ. §§ 12-6C-03 and 12-6C-11 and COMAR 10.34.22.05A(3)(d) and (n).

ORDER

Based upon an affirmative vote of a majority of the Board under the authority of Md. Code Ann., Health Occ. § 12-6C-11 and COMAR 10.34.22.05, it this 19th day of May, 2025, hereby,

ORDERED that Sagent Pharmaceuticals, Permit No. D07324, shall pay a FINE in the amount of FIVE THOUSAND DOLLARS (\$5,000.00), payable to the Maryland Board of Pharmacy within thirty (30) days of the date of this Order, and sent to:

Wells Fargo Bank
Attn: State of Maryland – Board of Pharmacy
Lockbox 2051
401 Market Street
Philadelphia, PA 19106

(Please include the Case Number 25-030 to ensure proper assignment.); and be it further,

ORDERED that Sagent Pharmaceuticals shall comply with all laws and regulations governing the wholesale distribution of prescription drugs and devices into, out of, and within the State of Maryland; and be it further,

ORDERED that in the event that Sagent Pharmaceuticals violates any of the terms above, the Board, after notice and an opportunity for a hearing, and a determination of a violation, may impose any disciplinary sanction it deems appropriate, including probation, suspension, revocation, and fines, said violation being proven by a preponderance of the evidence; and be it further,

ORDERED that this is a formal order and as such is a public document pursuant to Md. Code Ann., General Provisions Art. § 4-301 *et seq.*

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

10/10/2025 11:26:28 006

5-19-25

Date



Deena Speights Napata

Executive Director for:

Kristopher Rusinko, Pharm.D.

Board President

CONSENT

1. By signing this Consent, Sagent Pharmaceuticals submits to the foregoing Pre-Charge Consent Order as a resolution of this matter and agree to be bound by its terms and conditions.

2. Sagent Pharmaceuticals acknowledges the validity of this Pre-Charge Consent Order as if it were made after a hearing in which it would have had the right to counsel, to confront witnesses, and to all other substantial procedural protections provided by law.

3. Sagent Pharmaceuticals acknowledges that, by entering into this Pre-Charge Consent Order, Sagent Pharmaceuticals is waiving its right to appeal any adverse ruling of the Board that might have followed such an evidentiary hearing.

4. Sagent Pharmaceuticals acknowledges the legal authority and the jurisdiction of the Board to enter and enforce this Pre-Charge Consent Order.

5. Sagent Pharmaceuticals signs this Pre-Charge Consent Order freely and voluntarily, after having had the opportunity to consult with counsel. Sagent Pharmaceuticals fully understands the language, meaning, and effect of this Pre-Charge Consent Order.

Michael Joseph Parnell

28-91-


05/12/2025 112628-007

April 29 2025
Date

[Signature]
Name: Jeffrey Greve
Title: VP, CFO

STATE OF ILLINOIS,
COUNTY/CITY OF COOK:

I hereby certify that on this 29 day of April, 2025, before me, a Notary Public of the state and county/city aforesaid, personally appeared Jeffrey Greve, and made an oath in due form that the foregoing Consent was his/her voluntary act and deed on behalf of Sagent Pharmaceuticals.



Amy L. Sorapuru
Notary Public
My commission expires: 8/26/2025

[Handwritten signature]
[Faint handwritten text]

[Handwritten text]

05/12/2025 11:26:28 008

[Faint, illegible handwritten text]

